Can GLP-1 Agonists Reduce Risk for Severe Liver Disease?
GLP-1 agonists could be a treatment option to reduce the risk for major adverse liver outcomes in adults with type 2 diabetes and chronic liver disease.
Source: medscape.com
Axel Wester News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Axel Wester. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Axel Wester Today - Breaking & Trending Today
Scientists Discover New Life-Saving Benefit of Ozempic and Semaglutide
A nationwide study conducted by the Karolinska Institutet in Sweden, published in the journal Gut, indicates that the use of Ozempic and similar GLP1 agonists is linked to a lower likelihood of cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease. GLP1 agonists
Source: scitechdaily.com
GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease
For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes.
Source: empr.com
Diabetes drug Ozempic can reduce severe liver disease risk too
Novo Nordisk's Ozempic and other GLP1 agonists -- popular diabetes drugs -- are also associated with a reduced risk of developing cirrhosis and liver cancer in people with Type 2 diabetes and chronic liver disease, according to a study.GLP1 ...
Source: prokerala.com
Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients
Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.
Source: news-medical.net